Keyword: Jiangsu Hengrui Medicine
Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.
Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune from.
It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.
Hansoh and Hengrui chiefs together make one of biopharma's richest families; prosecutors grill top Samsung exec; FDA cites another Aurobindo plant.
After Hansoh Pharma's Hong Kong IPO, its helmswoman Zhong Huijuan and her husband, Jiangsu Hengrui's Sun Piaoyang, will be worth over $16 billion.
Celgene returning tislelizumab rights after Bristol-Myers wraps its buyout would have "marginal" effect, BeiGene Chief Adviser Eric Hedrick said.
Merck's Keytruda has leaped ahead of Bristol-Myers Squibb’s Opdivo and nabbed a green light in newly diagnosed non-small cell lung cancer.
The chairman of Zhifei Biological Products, which holds Chinese rights to Gardasil and Gardasil 9, boasted a net worth of about $4.6 billion Wednesday.